Mr. Rene Goehrum reports

BIOSYENT PHARMA TO INTRODUCE GELCLAIR® AT AHNS 11TH INTERNATIONAL CONFERENCE ON HEAD AND NECK CANCER

BioSyent Pharma Inc. is attending the American Head and Neck Society (AHNS) 11th International Conference on Head and Neck Cancer in Montreal, Que., on July 8 to July 12, 2023, to promote Gelclair, its new oncology supportive care product. Gelclair, indicated for the relief of the painful symptoms of oral mucositis, was in-licensed by BioSyent Pharma in December, 2022, and was approved by Health Canada in May, 2023. BioSyent Pharma is commencing the promotional launch of Gelclair in Canada and is planning to have the product available to Canadians in the fourth quarter of 2023.

"We are pleased to begin promoting Gelclair in Canada," said Rene Goehrum, president and chief executive officer of BioSyent. "This innovative product can make a difference in the quality of life of Canadian cancer patients suffering from oral mucositis. Gelclair represents BioSyent's first product in the oncology supportive care therapeutic area as we continue to focus on our strategic priorities of portfolio diversification and growth."

About oral mucositis

Oral mucositis is a painful condition often experienced by patients undergoing radiation or chemotherapy for cancer or bone marrow transplant. It is an inflammation and ulceration of the mucous membranes in the mouth and throat.

Dr. Murali Rajaraman, chair of the Atlantic Canada Radiation Medicine Council (ACRM) and associate professor at Dalhousie University's department of radiation oncology, stated that: "Oral mucositis is an important problem that can result in severe mouth pain making it difficult to eat, drink, swallow and, in some cases, even speak. It can significantly affect a cancer patient's quality of life and may lead that patient to delay or stop their cancer treatment. The prevention and management of oral mucositis remains a significant challenge for patients and their health care providers. It will be beneficial to have another product option available to patients to better manage oral mucositis."

About Gelclair

Gelclair is a protective gel that is indicated for the rapid relief of the painful symptoms of oral mucositis. It forms a barrier that adheres to the mucosa of the mouth, protecting and hydrating damaged tissue, shielding the exposed nerves from painful stimuli while eating and drinking, and thereby providing patients with fast pain relief.

Clinical studies have shown that Gelclair provides fast-acting pain relief, supports healing and improves the ability of patients suffering from oral mucositis to eat, drink, swallow and speak. Studies have also reported a decreased need for analgesics or opioids to reduce the pain of oral mucositis, as well as reductions in the grade of severity of oral mucositis with the use of Gelclair. Gelclair has demonstrated significantly better patient tolerability and acceptance than the standards of care it was compared with, helping patients to continue with their cancer treatments. Gelclair has no known pharmaceutical interactions and only rare, non-serious, reversible adverse events have been reported. Gelclair has demonstrated its safety and efficacy in helping to protect cancer patients from the severe pain associated with oral mucositis caused by radiotherapy or chemotherapy.

About BioSyent Inc.

BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been successfully developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals that treat these patients by marketing its products through its community, specialty and international business units.

We seek Safe Harbor.